Clinical Trial

Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata

Study acronym: NR3C1 and AA
Completed
View on ClinicalTrials.gov →
Summary
Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response. The rs41423247 polymorphism (BclI) may influence glucocorticoid sensitivity and disease activity. This study aims to investigate the association between NR3C1 rs41423247 polymorphism and susceptibility to alopecia areata and to evaluate its correlation with disease severity using the Severity of Alopecia Tool (SALT) score.
Trial Details
NCT Number NCT07455708
Lead Sponsor Benha University
Conditions Alopecia Areata(AA)
Enrollment 120 participants
Start Date 2023-11-01
Primary Completion 2024-11-01 (estimated)
Study Completion 2024-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-06